Bijan SalehizadehManaging Director & Co-Founder at NaviMed Capital
Dr. Salehizadeh has over 20 years of healthcare operational and investment experience. He currently serves as managing director and co-founder at NaviMed Capital, an investment firm based in Washington, DC where he focuses on private equity investments in healthcare and pharmaceutical services.
He has served on the board of directors of numerous private healthcare companies including Advantage Would & Surgical Care, CenterPointe Behavioral Health System (sold to Acadia Healthcare), The CM Group, Lighthouse Labs (sold), Velocity Clinical Research (sold), OPN Healthcare, Auris Health (sold to J&J for $5.75 billion), BÄRRX (sold to Covidien), Hyperion Therapeutics (IPO; sold to Horizon plc for $1.1 billion), Lumere (sold to GHX), and Opgen (IPO).
Dr. Salehizadeh holds an A.B. in Molecular Biology from Princeton University, an M.D. and Master’s in Science in Healthcare Policy from Columbia University, and an M.B.A. from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.